KRAS and neoplasm: Accumulating clinical evidence reveals that CRC is not solely a glycolytic tumor, but rather demonstrates increased expression of OXPHOS-related enzymes that drive invasion and metastasis in advanced stages, particularly in microsatellite-stable and KRAS-mutant subtypes [45, 46].